BioCentury | Oct 15, 2019
Company News

Oct. 14 Company Quick Takes: Shionogi, Ultragenyx, BridgeBio-Eidos and MolMed

...withdraws Zalmoxis application MolMed S.p.A. (Milan:MLM) withdrew a conditional marketing authorization in the EU for Zalmoxis...
...June, the company reported results from the Phase III TK008 study showing no advantage for Zalmoxis...
BioCentury | Aug 26, 2019
Company News

Modis deal bolsters Zogenix’s late-stage, rare disease pipeline

With its acquisition of Modis, Zogenix will need to blaze a regulatory trail for Modis’ thymidine kinase 2 deficiency program while still pushing its own Dravet syndrome therapy through regulatory approval. Zogenix Inc. (NASDAQ:ZGNX) said...
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...data in 74 patients; 38% SD but no CR or PR 3063 University of Michigan Ad-hCMV-TK...
BioCentury | Mar 14, 2019
Company News

GTx and Oncternal merging

..."GTX Shares Crater After Incontinence Readout" ). Shannon Lehnbeuter, Staff Writer Cirmtuzumab (UC-961) Selective androgen receptor degrader (SARD) TK216, TK-216 Receptor...
BioCentury | Oct 5, 2018
Financial News

Modis raises $30M series A for mitochondrial disorders

F-Prime Capital Partners and OrbiMed Advisors led a $30 million series A round for rare genetic disease company Modis Therapeutics Inc. (Oakland, Calif.). The round also included founding investor Aceras Life Sciences and new investor...
BioCentury | Oct 5, 2018
Finance

Modis’ mitochondrial modification

Compassionate use data from its lead program enabled rare genetic disease company Modis Therapeutics Inc. to attract $30 million in series A funding co-led by F-Prime Capital Partners and OrbiMed Advisors. Founding investor Aceras Life...
BioCentury | Oct 1, 2018
Financial News

Modis raises $30M series A for mitochondrial disorders

F-Prime Capital Partners and OrbiMed Advisors led a $30 million series A round for rare genetic disease company Modis Therapeutics Inc. (Oakland, Calif.). The round also included founding investor Aceras Life Sciences and new investor...
BioCentury | Jul 11, 2018
Preclinical News

Turning cancer cells against their own kind

...due to autotoxicity. The cells were also engineered to express herpes simplex virus thymidine kinase (HSV-TK...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Dec 21, 2017
Preclinical News

New pathway could overcome resistance to TKIs in cancer

...cells or increasing expression of genes in the ufmylation pathway could decrease drug resistance to TK...
Items per page:
1 - 10 of 171